Ofloxacin Ophthalmic Dosage
Apr 06, · What is ofloxacin ophthalmic? Ofloxacin is a fluoroquinolone (flor-o-KWIN-o-lone) antibiotic that fights bacteria in the body. Ofloxacin ophthalmic (for use in the eyes) is used to treat bacterial infections of the eyes. Ofloxacin ophthalmic is also used to treat an ulcer in the cornea of the eye. Ofloxacin will not treat a viral or fungal infection of the loveallfind.com name: Ocuflox. Mar 17, · Ophthalmic ofloxacin ophthalmic is used to treat bacterial infections of the eye, including conjunctivitis (pink eye) and ulcers of the cornea. Ofloxacin is in a class of medications called quinolone antibiotics. It works by killing bacterial cells that cause infection.
Medically reviewed by Drugs. Last updated on Oct 1, It is a fluorinated carboxyquinolone anti-infective for topical ophthalmic use. Inactives: sodium chloride and water for injection. Ofloxacin is a fluorinated 4-quinolone which differs from other fluorinated 4-quinolones in that there is a six member pyridobenzoxazine ring from positions 1 to 8 of the basic ring structure.
Pharmacokinetics: Serum, urine and tear concentrations of ofloxacin were measured in 30 healthy women at various time points during a ten-day course of treatment with Ofloxacin Ophthalmic Solution. The mean serum ofloxacin concentration ranged from 0. Maximum ofloxacin concentration increased from 1. Maximum serum ofloxacin concentrations after ten days of topical ophthalmic dosing were more than times lower than those reported after standard oral doses of ofloxacin.
Tear ofloxacin concentrations ranged from 5. Mean tear concentration measured four hours after topical ophthalmic dosing was 9. Corneal tissue concentrations of 4. Ofloxacin was excreted in the urine primarily unmodified. Microbiology: Ofloxacin has in vitro activity against a broad range of gram-positive and gram-negative aerobic and anaerobic bacteria.
Ofloxacin is bactericidal at concentrations equal to or slightly greater than inhibitory concentrations. Ofloxacin is thought to exert a bactericidal effect on susceptible bacterial cells by inhibiting DNA gyrase, an essential bacterial enzyme which is a critical catalyst in the duplication, transcription, and repair of bacterial DNA.
Cross-resistance has been observed between ofloxacin and other fluoroquinolones. There is generally no cross-resistance between ofloxacin and other classes of antibacterial agents such as beta-lactams or aminoglycosides. The safety and effectiveness of Ofloxacin Ophthalmic Solution in treating ophthalmologic infections due to the following organisms have not been established what does redemption mean in christianity adequate and well-controlled clinical trials.
Ofloxacin Ophthalmic Solution has what contraception is right for me quiz shown to be active in vitro against most strains of these organisms but the clinical significance in ophthalmologic infections is unknown.
Conjunctivitis: In a randomized, double-masked, multi-center clinical trial, Ofloxacin Ophthalmic Solution was superior to its vehicle after 2 days of treatment in patients with conjunctivitis and positive conjunctival cultures. Please note that microbiologic eradication does not always correlate with clinical outcome in anti-infective trials. The median time to clinical success was 11 days for the ofloxacin treated group and 10 days for the fortified treatment group.
Ofloxacin Ophthalmic Solution is indicated for the treatment of infections caused by susceptible strains of the following bacteria in the conditions listed below:. Ofloxacin Ophthalmic Solution is contraindicated in patients with a history of hypersensitivity to ofloxacin, to other quinolones, or to any of the components in how to get into motorbike racing medication see WARNINGS.
Ofloxacin Ophthalmic Solution should not be injected subconjunctivally, nor should it be introduced directly into the anterior chamber of the eye. Some reactions were accompanied by cardiovascular collapse, loss of consciousness, angioedema including laryngeal, pharyngeal or facial edemaairway obstruction, dyspnea, urticaria, and itching.
A rare occurrence of Stevens-Johnson syndrome, which progressed to toxic epidermal necrolysis, has been reported in a patient who was receiving topical ophthalmic ofloxacin. If an allergic reaction to ofloxacin occurs, discontinue the drug. Serious acute hypersensitivity reactions may require immediate emergency treatment.
Oxygen and airway management, including intubation should be administered as clinically indicated. General: As with other anti-infectives, prolonged use may result in overgrowth of nonsusceptible organisms, including fungi. If superinfection occurs discontinue use and institute alternative therapy. Whenever clinical judgment dictates, the patient should be examined with the aid of magnification, such as slit lamp biomicroscopy and, where appropriate, fluorescein staining. Ofloxacin should be discontinued at the first appearance of a skin rash or any other sign of hypersensitivity reaction.
The systemic administration of quinolones, including ofloxacin, has led to lesions or erosions of the cartilage in weight-bearing joints and other signs of arthropathy in immature animals of various species.
Information for Patients: Avoid contaminating the applicator tip with material from the eye, fingers or other source. Systemic quinolones, including ofloxacin, have been associated with hypersensitivity reactions, even following a single dose. Discontinue use immediately and contact your physician at the first sign of a rash or allergic reaction.
Drug Interactions: Specific drug interaction studies have not been conducted with Ofloxacin Ophthalmic Solution. However, the systemic administration of some quinolones has been shown to elevate plasma concentrations of theophylline, interfere with the metabolism of caffeine, and enhance the effects of the oral anticoagulant warfarin and its derivatives, and has been associated with transient elevations in serum creatinine in patients receiving cyclosporine concomitantly.
Carcinogenesis, Mutagenesis, Impairment of Fertility: Long term studies to determine the carcinogenic potential of ofloxacin have not been conducted. What is ofloxacin ophthalmic solution was not mutagenic in the Ames test, in vitro and in vivo cytogenic assay, sister chromatid exchange assay Chinese hamster and human cell linesunscheduled DNA synthesis UDS assay using human fibroblasts, the dominant lethal assay, or mouse micronucleus assay.
Ofloxacin was positive in the UDS test using rat hepatocyte, and in the mouse lymphoma assay. These dosages resulted in decreased fetal body weight and increased fetal mortality in rats and rabbits, respectively. There are, however, no adequate and well-controlled studies in pregnant women. Ofloxacin Ophthalmic Solution should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.
Nursing Mothers: In nursing women a single mg oral dose resulted in concentrations of ofloxacin in milk which were similar to those found in plasma. It is not known whether ofloxacin is excreted in human milk following topical ophthalmic administration. Because of the potential for serious adverse reactions from ofloxacin in nursing infants, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance how to make subwoofers louder the drug to the mother.
Pediatric Use: Safety and effectiveness in infants below the age of one year have not been established. Quinolones, including ofloxacin, have been shown to cause arthropathy in immature animals after oral administration; however, topical ocular administration of ofloxacin to immature animals has not shown any arthropathy.
There is no evidence that the ophthalmic dosage form of ofloxacin has any effect on weight bearing joints. Geriatric Use: No overall differences in safety or effectiveness have been observed between elderly and younger patients. Ophthalmic Use: The most frequently reported drug-related adverse reaction was transient ocular burning or discomfort.
Rare reports of dizziness and nausea have been received. The recommended dosage regimen for the treatment of bacterial conjunctivitis is:. The recommended dosage regimen for the treatment of bacterial corneal ulcer is:. Ofloxacin Ophthalmic Solution.
Gram-positive bacteria: Gram-negative bacteria: Staphylococcus aureus Enterobacter cloacae Staphylococcus epidermidis Haemophilus influenzae What is ofloxacin ophthalmic solution pneumoniae Proteus mirabilis Pseudomonas aeruginosa. Days 1 and 2 Instill one to two drops every two to four hours in the affected eye s.
Days 3 through 7 Instill one to two drops four times daily. Days 1 and 2 Instill one to two drops into the affected eye every 30 minutes, while awake. Awaken at approximately four and six hours after retiring and instill one to two drops. Days 3 through 7 to 9 Instill one to two drops hourly, while awake.
Days 7 to 9 through treatment completion Instill one to two drops, four times daily. Labeler - Henry Schein Inc. Antibiotics Drug Status Availability Prescription only Rx. Akorn, Inc. Prasco Laboratories Rising Pharmaceuticals, Inc. Drug Class. Ophthalmic anti-infectives. Related Drugs. Subscribe to our newsletters. FDA Safety Alerts for all medications. Daily MedNews.
Staphylococcus hominus. Citrobacter freundii. Staphylococcus simulans. Enterobacter aerogenes. Streptococcus pyogenes.
Nov 28, · Ofloxacin Ophthalmic Solution USP, % is a sterile ophthalmic solution. It is a fluorinated carboxyquinolone anti-infective for topical ophthalmic use. Chemical Name: (±)Fluoro-2, 3-dihydromethyl(4-methylpiperazinyl)oxo-7H-pyrido [1,2,3-de]-1,4 benzoxazinecar boxy lie acid. Ofloxacin ophthalmic solution (Ocuflox ®) is an antibiotic eye drop. It is used to treat certain bacterial infections of the eye, including conjunctivitis (also called " pink eye ") and corneal ulcers. Using Ofloxacin Ophthalmic Solution for Conjunctivitis. Ofloxacin Ophthalmic Solution is unbuffered and formulated with a pH of (range - to ). It has an osmolality of mOsm/kg. Ofloxacin is a fluorinated 4-quinolone which differs from other fluorinated 4-quinolones in that there is a six member (pyridobenzoxazine) ring from positions 1 to 8 of the basic ring structure.
Medically reviewed by Drugs. Last updated on May 1, Days 1 and 2: Instill 1 to 2 drops in the affected eye s every 2 to 4 hours. Days 3 through 7: Instill 1 to 2 drops in the affected eye s 4 times a day. Use: For the treatment of bacterial conjunctivitis due to susceptible strains of Staphylococcus aureus, S epidermidis, Streptococcus pneumoniae, Enterobacter cloacae, Haemophilus influenzae, Proteus mirabilis, Pseudomonas aeruginosa. Days 1 and 2: Instill 1 to 2 drops in the affected eye s every 30 minutes while awake and about 4 and 6 hours after retiring.
Days 3 through 7 to 9: Instill 1 to 2 drops in the affected eye s every hour while awake. Days 7 to 9 through treatment completion: Instill 1 to 2 drops in the affected eye s 4 times a day. Use: For the treatment of bacterial corneal ulcers due to susceptible strains of S aureus, S epidermidis, S pneumoniae, P aeruginosa, Serratia marcescens, Propionibacterium acnes. Use: For the treatment of bacterial conjunctivitis due to susceptible strains of S aureus, S epidermidis, S pneumoniae, E cloacae, H influenzae, P mirabilis, P aeruginosa.
Use: For the treatment of bacterial corneal ulcers due to susceptible strains of S aureus, S epidermidis, S pneumoniae, P aeruginosa, S marcescens, P acnes. Safety and efficacy have not been established in patients younger than 1 year. Administration advice : -For topical ophthalmic use only not for injection -Do not inject subconjunctivally; do not introduce directly into the anterior chamber of the eye.
Patient advice : -Do not wear contact lenses during therapy. Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances. Ofloxacin Ophthalmic Dosage Medically reviewed by Drugs. Applies to the following strengths: 0. Antibiotics Drug Status Availability Prescription only Rx. Akorn, Inc. Prasco Laboratories Rising Pharmaceuticals, Inc.
Email address. Select one or more newsletters to continue.